Conditions: Spondylarthropathies
Keywords: seronegative oligoarthritis infliximab intraarticular
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 1
Healthy volunteers: no

Brief summary:
The aim of this study is to establish the efficacy and duration of effect of intra-articular (IA) infliximab vs intravenous infliximab vs current standard care (IA steroid injections) in seronegative oligoarthritis. All patients will have seronegative arthritis affecting less than 5 joints but including at least one knee. 10 patients will receive IA infliximab injections to the affected knee, 10 will receive IA steroid injections to the affected knee and 10 will receive a course of intravenous infliximab. Patients will not be aware of their group as this is a placebo-controlled study.

Detailed description:

Arms:
arm 1: Intra-articular injection of steroid (80mg depomedrone) arm 2: intra-articular injection of 100mg infliximab arm 3: intravenous infusions of infliximab given at 0, 2, 6 and 14 weeks at a dose of 5mg/kg (patient body weight)

Interventions: intervention 1: methylprednisolone intervention 2: Infliximab intervention 3: Infliximab
Intervention descriptions: intervention 1: intra-articular injection of methylprednisolone (80mg given at baseline only) intervention 2: intra-articular injection of 100mg infliximab given at baseline only intervention 3: intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14

Protocol document: